Introduction
The pathogenesis of RA and PsA is complex and only partially understood [1, 2] . Several pathways and mediators may be involved in the pathogenesis of RA and PsA, including TNF [2, 3] and IL-17A [47] . Inhibition of TNF or to a lesser extent IL-17A has been shown to improve joint symptoms in RA [8, 9] ; inhibition of either TNF or IL-17A has been shown to improve joint and skin symptoms and quality of life in patients with PsA [1016] . It is hypothesized that concurrent inhibition of TNF and IL-17A may improve outcomes in patients with RA or PsA; however, it is unknown whether dual inhibition will result in a reasonable safety profile or have additive efficacy outcomes.
ABT-122 is a dual-variable domain immunoglobulin that binds human TNF and IL-17A in a fixed 1:1 ratio [17, 18] . ABT-122 suppressed chemokines associated with inflammation and was well tolerated overall at clinically relevant doses in phase 1 studies [19, 20] . In a randomized, double-blind, active-controlled, parallel-group study in patients with active RA and an inadequate response to MTX (NCT02141997), simultaneous inhibition of TNF and IL-17A by ABT-122 produced a safety profile equivalent to that observed with inhibition of TNF alone by adalimumab [21] . However, as evaluated with ACR responses of 520, 550 and 570% improvement (ACR20, ACR50 and ACR70, respectively), the efficacy of ABT-122 120 mg every other week (EOW; ACR20, 75.0%; ACR50, 46.4%; ACR70, 17.9%) and 120 mg every week (EW; ACR20, 80.0%; ACR50, 47.3%; ACR70, 36.4%) did not differ substantially from that of adalimumab 40 mg EOW (ACR20, 67.9%; ACR50, 48.2%; ACR70, 21.4%) in these patients with RA receiving concomitant MTX over 12 weeks. Likewise, in a double-blind, placebo-controlled, parallelgroup study in patients with PsA and an insufficient response to MTX (NCT02349451), ABT-122 120 mg EW (ACR20, 64.8%; ACR50, 36.6%; ACR70, 22.5%) or 240 mg EW (ACR20, 75.3%; ACR50, 53.4%; ACR70, 31.5%) displayed safety and efficacy that were not clearly differentiated from that of adalimumab 40 mg EOW (ACR20, 68.1%; ACR50, 37.5%; ACR70, 15.3%) over 12 weeks, despite some significant differences for the higher dose of ABT-122 vs adalimumab in terms of ACR50 and ACR70 [22] . This article reports on the longer-term safety and maintenance of efficacy with ABT-122 for an additional 24 weeks in patients with RA or PsA who enrolled in open-label extensions (OLEs) of the 12-week, randomized, double-blind studies.
Methods
These studies (ClinicalTrials.gov, NCT02433340 and NCT02429895) were conducted in accordance with guidance from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and adhered to the principles in the Declaration of Helsinki. An independent ethics committee or institutional review board at each study site approved the protocol. Every patient provided written informed consent.
Study design

RA
The design of the phase 2, 12-week, randomized, doubleblind, active-controlled, parallel-group study (NCT02141997) in patients (518 years of age) with active RA for 53 months per the ACR criteria receiving concomitant MTX has been previously described [21] . Briefly, after screening, patients were randomized (1:1:1:1) to receive one of three ABT-122 doses (60 mg SC EOW, 120 mg SC EOW or 120 mg SC EW) or adalimumab 40 mg SC EOW for 12 weeks. The randomized study enrolled 49 patients from the USA and 173 patients from elsewhere. Patients outside the USA who completed the 12-week double-blind period were eligible for the 24-week OLE, and were enrolled from 30 sites in the European Union (Bulgaria, Czech Republic, Germany, Hungary, Poland and Romania) and New Zealand. During the OLE, all patients received ABT-122 120 mg SC EOW with options for one extra 120 mg dose (for inadequate efficacy) or a decrease to 60 mg EOW (for safety reasons).
PsA
The design of the phase 2, 12-week, randomized, doubleblind, placebo-controlled, parallel-group study in patients (518 years of age) with active PsA, defined as a diagnosis fulfilling the Classification Criteria for Psoriatic Arthritis [23] for 53 months and 53 tender joints and 53 swollen joints at screening and 51 psoriatic plaque of 52 cm in diameter and an inadequate response to MTX, has been previously described [22] . The PsA OLE study was terminated early by the sponsor due to the lack of sufficient differentiation from adalimumab observed in the randomized controlled trial.
After the screening period, patients continued to receive MTX and were randomized 3:3:3:1 to also receive ABT-122 120 mg EW, ABT-122 240 mg EW, adalimumab 40 mg EOW or matching placebo SC for 12 weeks. The randomized study enrolled 42 patients from the USA and 198 patients from elsewhere. After completion of the 12-week double-blind phase, patients outside the USA could enter a 24-week OLE in which all patients received ABT-122 240 mg EOW. Patients were enrolled from 35 sites in the European Union (Bulgaria, Czech Republic, Germany, Hungary, Latvia, Poland, Romania and Spain), Australia and New Zealand. During the OLE, there were options for one extra 240 mg dose (for inadequate efficacy) or a decrease to 120 mg EOW (for safety reasons).
Safety assessments
In both studies, adverse events (AEs) and laboratory parameters were monitored during the entire study periods. AEs were coded using the Medical Dictionary for Regulatory Activities, version 17.1 (RA study) or 19.1 (PsA study) according to preferred term and system organ class. Treatment-emergent AEs (TEAEs) were categorized by study drug assignment and relationship to study drugs. Investigators determined the severity of TEAEs according to the Rheumatology Common Toxicity Criteria (CTC), version 2.0 [24] .
Immunogenicity assessments
In the RA OLE study, blood was drawn to measure ABT-122 concentrations and binding anti-ABT-122 antibodies at weeks 0, 4, 8, 12, 16, 20 and 24 and at any unscheduled visit resulting from dose adjustment. Planned immunogenicity analyses in the PsA study were not completed because the study was terminated early. Assessment of neutralizing antibodies was not conducted in these phase 2 studies.
Efficacy assessments
Maintenance of efficacy in the RA OLE was evaluated by the proportion of patients achieving 520, 550 and 570% improvements in the ACR response criteria (ACR20/50/70) at week 24, 28-joint DAS based on high sensitivity CRP [DAS28 (hsCRP)] <3.2 and <2.6 at week 24, and Clinical Disease Activity Index 410 and 42.8 at week 24, and the mean change from baseline over time in DAS28 (hsCRP).
For the PsA OLE study, maintenance of efficacy was evaluated by ACR20/50/70 responses over time and changes from baseline in DAS28 (hsCRP) and Spondyloarthritis Research Consortium of Canada Enthesitis Index over time. In addition, Psoriasis Area and Severity Index (PASI) response rate (550/575/ 590% improvement) over time in patients who had 53% of body surface area affected by psoriasis at baseline was measured.
The baseline for calculation of efficacy outcomes in both OLE studies was the start of their respective double-blind studies.
Statistics and analyses
For the RA OLE study, missing data were replaced by using non-responder imputation. In the PsA OLE, because it was terminated earlier than planned and many patients would have been inappropriately counted as non-responders, missing data were not imputed; rather, observed cases are shown. In both studies, efficacy was analysed in all patients who received one or more dose of ABT-122 in the OLE. Descriptive statistics are presented (SAS version 9.2 or higher, SAS Institute, Cary, NC, USA) and no formal statistical comparisons were performed.
Results
Patients
Among the 158 patients enrolled in the RA OLE study, 150 (95%) completed the 24-week treatment (Fig. 1A) . Eight patients (5%) prematurely discontinued, mainly because of withdrawal of consent. Most patients were women, most were white, the mean age was 55 years, and the mean RA disease duration was 7.8 years ( Table 1) . The median (range) duration of exposure to ABT-122 during the OLE was 165 (25179) days. Five patients (3%) received one extra dose of ABT-122 120 mg EOW (for inadequate efficacy); in two patients (1%), the dose of ABT-122 was decreased to 60 mg EOW (for safety reasons).
A total of 168 patients were enrolled in the PsA OLE study and 139 (83%) discontinued (Fig. 1B) , primarily due to early termination of the study by the sponsor. Approximately equal numbers of patients were men and women, most were white, the mean age was 48 years, and the mean PsA disease duration was 7.4 years ( Table 1) . The median (range) duration of exposure to ABT-122 during the OLE was 107 (11167) days.
Safety
AEs
In the RA OLE study, 65 patients (41%) reported 51 TEAE (Table 2) . Most TEAEs were mild or moderate in severity. Serious AEs (SAEs) were reported in six patients, who had a total of eight distinct events. There were no reports of serious infections; however, two patients had SAEs suggestive of infection: one (0.6%) SAE of enterocolitis and one (0.6%) SAE of inflammation of the wound with skin ulcer. Non-serious events of upper respiratory tract infection (n = 15; 9%) and nasopharyngitis (n = 4; 3%) were the most frequently reported infections overall. There was one non-serious report of basal cell carcinoma, one serious myocardial ischaemic event and two non-serious reports of liver events (transient elevation of aspartate transaminase and liver steatosis/hepatobiliary disease). There were no deaths, systemic hypersensitivity reactions, severe injection site reactions, cardiac failures, haematological AEs or demyelinating disorders.
In the PsA OLE study, 96 patients (57%) reported 51 TEAE (Table 2) . One severe TEAE (rash) was reported; other TEAEs were mild or moderate in severity. Infections developed in 45 patients (27%), the most common of which were upper respiratory tract infection (n = 10; 6%) and nasopharyngitis (n = 6; 4%). A total of four SAEs were reported in a single patient and were related to a motor vehicle accident. Thirteen patients (8%) had 51 hepatic TEAE, including 12 patients with increased liver enzymes and one patient with a mild hepatic cyst. There were no deaths or TEAEs of serious infection, malignancy, systemic hypersensitivity reaction, haematological disorder, cardiac failure, demyelinating disorder or ischaemic events.
Laboratory abnormalities
There were few laboratory abnormalities reported as OMERACT CTC grade 3 or 4 shifts in the RA OLE study. There were no neutrophil or white blood cell abnormalities greater than grade 2; grade 2 neutrophil abnormalities were reported in nine patients (6%; Table 3). One patient had an event of abnormal alanine aminotransferase (147 U/L) and two events of abnormal serum aspartate aminotransferase (134 and 123 U/L) that were grade 3 [3.18.0 Â upper limit of normal (ULN)]. The patient with elevations in liver enzymes had bilirubin levels of 0.42 Â ULN or lower at each assessment. One patient had abnormal bilirubin that was grade 3 (2.03.0 Â ULN). Four patients had haemoglobin abnormalities of grade 3 (n = 3; 2%) or grade 4 (n = 1; 0.6%). Eighteen patients (12%) had grade 3 lymphocyte abnormalities. Most grades 3 and 4 haemoglobin and lymphocyte abnormalities were isolated or intermittent and resolved.
In the PsA OLE study, there were few OMERACT CTC grade 3 or 4 changes in mean laboratory values; shifts in laboratory values in individual patients were infrequent and usually resolved normally. There were no neutrophil or white blood cell count abnormalities greater than grade 2; grade 2 neutrophil abnormalities were reported in six patients (4%). Four patients had abnormal alanine aminotransferase levels (187, 219 and 229 U/L; one patient had two events, 209 and 186 U/L) and one patient had abnormal aspartate aminotransferase levels (115 U/L) that were grade 3. The patients with elevations in liver enzymes had bilirubin levels of 1.53 Â ULN or lower at each assessment. Two patients had abnormal bilirubin that was grade 3 (2.03.0 Â ULN). Three patients had haemoglobin abnormalities of grade 3 (n = 2; 1%) or grade 4 (n = 1; 0.6%). Five patients (3%) had grade 3 lymphocyte abnormalities. Most grades 3 and 4 haemoglobin and lymphocyte abnormalities were isolated or intermittent and resolved.
Immunogenicity
During the RA OLE, some patients exhibited a reduction in serum ABT-122 concentrations below the lower limit of quantification (LLOQ). The percentage of patients with serum ABT-122 concentrations below the LLOQ was stable among those previously treated with ABT-122 60 mg EOW ($35%) or ABT-122 120 mg EOW ($15%) in the RA 12-week, randomized, double-blind study. After reassignment to ABT-122 during the OLE, the percentages of patients with ABT-122 serum concentrations below the LLOQ increased initially, then appeared to plateau (at $20%) by week 8 among those previously treated with adalimumab 40 mg EOW or ABT-122 120 mg EW (supplementary Fig. S1 , available at Rheumatology online). Anti-ABT-122 antibody incidence at baseline of the RA OLE was 65% (24/37), 23% (9/39) and 20% (8/ 40) among patients who received prior treatment with ABT-122 60 mg EOW, 120 mg EOW and 120 mg EW dose groups, respectively (not tested in the prior adalimumab group), in the RA 12-week, randomized, double-blind study. At week 24, anti-ABT-122 antibody incidence was 60% (21/35), 63% (24/38), 53% (20/38) and 45% (18/40) among patients who received prior treatment with ABT-122 60 mg EOW, ABT-122 120 mg EOW, ABT-122 120 mg EW and adalimumab 40 mg EOW, respectively, in the RA 12-week, randomized, double-blind study. Because the PsA OLE study was prematurely terminated, no immunogenicity analysis was performed. Neutralizing antibodies were not assessed in either study. 
Efficacy
The efficacy of ABT-122 was maintained during the 24-week RA OLE study. The ACR20, ACR50 and ACR70 responses at the end of the OLE (week 24; 72, 49 and 31%, respectively) were similar to responses at the end of the randomized double-blind study based on an nonresponder imputation analysis of all patients receiving adalimumab or ABT-122 (week 0; 77, 46 and 26%, respectively; Fig. 2A ). In addition, disease activity responses as assessed by DAS28 (hsCRP) <3.2 and <2.6 (Fig. 2B) , Clinical Disease Activity Index 410 and 42.8 (supplementary Fig. S2 , available at Rheumatology online) and decreases from baseline in DAS28 (hsCRP) (Fig. 2C) were also maintained during the 24-week OLE. In the PsA OLE, ACR20, ACR50 and ACR70 responses were stable during the OLE (Fig. 3A) based on an as-observed analysis; at week 4, ACR20, ACR50 and ACR70 Infections in one patient each in the RA OLE were atypical pneumonia, cystitis, herpesvirus infection, oral herpes, parametritis, paronychia, pneumonia, pulpitis dental, pustular rash, respiratory tract infection, sinusitis, tonsillitis, varicella and viral upper respiratory tract infection, and in the PsA OLE were angular cheilitis, conjunctivitis, herpes simplex, herpesvirus infection, lower respiratory tract infection, oral infection, otitis media, paronychia, purulent discharge, respiratory tract infection, sinusitis, tooth infection, viral infection, viral sinusitis, viral upper respiratory tract infection and wound infection. EOW: every other week; OLE: open-label extension; TEAE: treatment-emergent adverse event.
responses were 77, 48 and 24%, respectively, and at week 24 they were 78, 50 and 26%, respectively. Changes from baseline in the original randomized trial for DAS28 (hsCRP) (Fig. 3B) , PASI50, PASI75 and PASI90 responses (Fig. 3C) , and changes from baseline in Spondyloarthritis Research Consortium of Canada Enthesitis Index (Fig. 3D) were also stable during the 24-week OLE.
Discussion
In previous 12-week, randomized, double-blind studies, simultaneous inhibition of TNF and IL-17A with ABT-122 was efficacious and resulted in an acceptable safety profile in patients with RA [21] or PsA [22] receiving MTX. However, in these studies, for most clinical responses, ABT-122 could not be meaningfully differentiated from adalimumab. In these 24-week OLE studies, we assessed the safety and maintenance of efficacy of ABT-122 in eligible patients with RA or PsA receiving MTX concurrently.
ABT-122 was well tolerated, and there were no new safety findings identified with dual cytokine blockade of TNF and IL-17A over an additional period of 24 weeks in these studies. Notably, the incidence of SAEs and serious infections remained low with the use of a dual-variable domain immunoglobulin targeting two cytokines, in contrast to other studies that treated patients with two unique biological DMARDs [2527] . In both the RA and PsA OLE studies, the incidence of infections with ABT-122 was not different from the incidence observed in the 12-week double-blind RA or PsA studies with ABT-122 [21, 22] . The overall frequency of TEAEs with ABT-122 in the RA OLE study was similar to the double-blind RA study [21] , whereas the frequency of TEAEs with ABT-122 in the PsA OLE study was numerically higher compared with ABT-122 in the double-blind PsA study [22] . The comparability of the safety of ABT-122 in the present OLE studies and the 12-week, randomized, double-blind studies [21, 22] suggests that simultaneous inhibition of TNF and IL-17A with a single antibody that binds to both of these proinflammatory molecules did not raise the risk of AEs over a longer treatment period. Consistent with the literature, patients with PsA have different AE profiles compared with patients with RA, and this was observed in the RA and PsA OLE studies. For example, hepatic AEs were more frequent in the present PsA study compared with the RA study, which is in line with a literature report that liver enzyme abnormalities are significantly more common in patients with PsA than in patients with RA [28] .
In the RA OLE study, the overall anti-ABT-122 antibody incidence at baseline was numerically greater in patients who had previously received ABT-122 60 mg EOW in the RA 12-week, randomized, double-blind study (65%), compared with patients who received ABT-122 EW (baseline incidence, 2023%). A numerically higher incidence of anti-ABT-122 antibodies with a lower and less frequent dosing regimen of ABT-122 is not unexpected, since less frequent administration of a lower dose results in lower trough levels, which has been associated with the development of antidrug antibodies [29, 30] . At week 24, the incidence of anti-ABT-122 antibodies was comparable across patient groups ($5060%) regardless of the prior treatment they received in the RCT. Nonetheless, the efficacy of ABT-122 observed in the 12-week, randomized, double-blind studies was maintained during the 24-week OLE studies, suggesting that these anti-ABT-122 antibodies did not have a clinical impact. Neutralizing antibodies were not tested in these studies.
Strengths of these OLE studies included the ability to follow patients for up to 36 total weeks of treatment, which allowed for the assessment of the safety profile of ABT-122 with longer-term treatment, as well as the high completion percentages (excepting discontinuations related to ending the PsA OLE study). Limitations include the relatively small numbers of patients, which precluded vigorous subgroup analyses and the open-label nature of the studies.
Although ABT-122 binds human TNF and IL-17A [17, 18] and suppresses chemokines associated with inflammation [19, 20] , the efficacy of ABT-122 was not sufficiently differentiated from that of comparators in the randomized double-blind controlled studies [21, 22] . In the RA randomized double-blind controlled study, the average molar serum concentration of ABT-122 at a dose of 120 mg EOW was shown to be comparable to adalimumab at a dose of 40 mg EOW [21] . Furthermore, the exposures of ABT-122 doses of 120 mg EW and 240 mg EW were estimated to be two and four times higher, respectively, than that of adalimumab 40 mg EOW. This suggests that the anti-IL-17A component does not significantly add to the efficacy of ABT-122 and that the effects of ABT-122 are mostly due to inhibition of TNF.
In conclusion, ABT-122 demonstrated acceptable tolerability and maintenance of efficacy, despite the presence of anti-ABT-122 antibodies in some patients, when administered for up to 36 weeks in patients with RA or PsA receiving background MTX, including patients who switched from adalimumab to ABT-122 and those switching from a lower dose to a higher dose of ABT-122. Despite the overall safety of ABT-122, because of the lack of clinically important differentiation from TNF inhibition alone as provided by adalimumab, further development of ABT-122 for the treatment of PsA and RA is not being pursued. AbbVie. AbbVie and the authors thank the patients who participated in the clinical trial and all study investigators for their contributions. Results of this article were presented in part at the ACR/AHRP Annual Scientific Meeting, 11 November 2016, Washington, DC. All authors contributed to the development of the content, all authors and AbbVie reviewed and approved the final manuscript, and the authors maintained control over the final content.
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